Ipsen (Ipsen)

Oncology Corporate Profile

Company Description

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding __┬┤1.2 billion in 2013. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.

Website: http://www.ipsen.com

Brand Generic Indication
Somatuline® DepotlanreotideSomatuline® Depot is a somatostatin analog indicated for:
-the long-term treatment of acromegalic patients who have had an
inadequate response to or cannot be treated with surgery and/or radiotherapy.
-the treatment of adult patients with unresectable, well- or moderatelydifferentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
-the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
somatulinesomatostatin analog inhibitorNeuroendocrine tumorIII
decapeptyl (triptorelin pamoate)decapeptide analogueProstate cancerIII
tasquinimodoral quinolone-3-carboxamidProstate cancerIIActive Biotech
tasquinimodoral quinolone-3-carboxamidVarious cancer typesII

View additional information on product candidates here »

Source: http://www.ipsen.com

Recent News Headlines

There are no news items to display